The B-MYB proto-oncogene is a transcription factor belonging to the MYB family that is frequently overexpressed or amplified in different types of human malignancies. While it is suspected that B-MYB plays a role in human cancer, there is still no direct evidence of its causative role. Looking for mutations of the B-MYB gene in human cell lines and primary cancer samples, we frequently isolated two nonsynonymous B-MYB polymorphic variants (rs2070235 and rs11556379). Compared to the wild-type protein, the B-MYB isoforms display altered conformation, impaired regulation of target genes and decreased antiapoptotic activity, suggesting that they are hypomorphic variants of the major allele. Importantly, the B-MYB polymorphisms are common; rs2070235 and rs11556379 are found, depending on the ethnic background, in 10-50% of human subjects. We postulated that, if B-MYB activity is important for transformation, the presence of common, hypomorphic variants might modify cancer risk. Indeed, the B-MYB polymorphisms are underrepresented in 419 cancer patients compared to 230 controls (odds ratio 0.53; (95%) confidence interval 0.385-0.755; P ¼ 0.001). This data imply that a large fraction of the human population is carrier of B-MYB alleles that might be associated with a reduced risk of developing neoplastic disease.
The B-MYB proto-oncogene is a transcription factor belonging to the MYB family that is frequently overexpressed or amplified in different types of human malignancies. While it is suspected that B-MYB plays a role in human cancer, there is still no direct evidence of its causative role. Looking for mutations of the B-MYB gene in human cell lines and primary cancer samples, we frequently isolated two nonsynonymous B-MYB polymorphic variants (rs2070235 and rs11556379). Compared to the wild-type protein, the B-MYB isoforms display altered conformation, impaired regulation of target genes and decreased antiapoptotic activity, suggesting that they are hypomorphic variants of the major allele. Importantly, the B-MYB polymorphisms are common; rs2070235 and rs11556379 are found, depending on the ethnic background, in 10-50% of human subjects. We postulated that, if B-MYB activity is important for transformation, the presence of common, hypomorphic variants might modify cancer risk. Indeed, the B-MYB polymorphisms are underrepresented in 419 cancer patients compared to 230 controls (odds ratio 0.53; (95%) confidence interval 0.385-0.755; P ¼ 0.001). This data imply that a large fraction of the human population is carrier of B-MYB alleles that might be associated with a reduced risk of developing neoplastic disease. Oncogene (2008 Oncogene ( ) 27, 2929 Oncogene ( -2933 doi:10.1038/sj.onc.1210947; published online 19 November 2007 Keywords: transcription; neuroblastoma; colon cancer; leukaemia; apoptosis B-MYB is a putative proto-oncogene required for mammalian development and involved in cell proliferation and survival (Oh and Reddy, 1999; Tanaka et al., 1999; Sala, 2005) . Although there is still no evidence of its direct involvement in human cancer, several studies have revealed that B-MYB is either amplified or overexpressed in different human malignancies, while its expression in neuroblastoma patients correlates with poor survival (Raschella et al., 1999; Forozan et al., 2000; Tanner et al., 2000; Bar-Shira et al., 2002) . Further evidence that B-MYB is involved in tumorigenesis is its ability to cooperate with activated ras in transforming mouse fibroblasts (Masselink et al., 2001) . Aberrant B-MYB expression might promote cancer development through increased activity of downstream target genes. B-MYB target genes have been found that promote cell cycle progression or resistance to apoptosis, although B-MYB effects might also occur through other mechanisms (Oh and Reddy, 1999; Sala, 2005 ). While the above described studies support the hypothesis that B-MYB is a proto-oncogene, a recent report shows that an inactivating mutation of B-MYB in zebrafish actually promotes chemical carcinogenesis as a consequence of genomic destabilization (Shepard et al., 2005) . Thus, an interesting scenario is emerging where increased B-MYB expression or its inactivating mutations can both result in tumorigenesis. One could speculate that an optimal range of B-MYB expression is required for normal cell homeostasis and its abnormal activity-either too high or too low-could impinge on the development of neoplastic disease.
Differences in B-MYB activity could be attained by regulation of its mRNA levels, protein stability or by somatic mutations. We found no evidence of B-MYB mutations in several cancer cell lines or tumor biopsies. Instead, we frequently isolated two nonsynonymous polymorphic variants, S427G (rs2070235) and I624M (rs11556379). Serine 427 is highly conserved from Drosophila to humans, while isoleucin 624 is located in a poorly conserved region of B-MYB.
To investigate whether the amino acid changes result in altered B-MYB conformation, we exposed lysates of 293 cells transfected with the different B-MYB variants to tryptic digestion. A single nucleotide polymorphism (SNP)-induced conformational change will be reflected (Nicoletti et al., 1991) . Values in the y axis indicate the percentage of cell death in the different transfectants and error bars indicate standard deviations. The differences of cell death between cells transfected with wild-type B-MYB or the polymorphic isoforms were small but statistically significant (paired Student's t-test, *P ¼ 0.009; **P ¼ 0.002, with respect to wild-type B-MYB, n ¼ 6). (c) Activated caspase-3 immunohistochemical assay. 293 cells were plated onto glass coverslip, transfected with the different B-MYB plasmids and exposed to H 2 O 2 . Exogenous B-MYB was detected with a X-press antibody and apoptotic cells were marked by an antibody recognizing activated caspase-3. B-MYB and caspase-3-positive cells were detected with secondary antibodies conjugated to FITC and Texas-red, respectively. Error bars indicate standard deviations and statistical assessment shows that the difference between wild-type B-MYB and the polymorphic isoforms is significant (paired Student's t-test. *P ¼ 0.047; **P ¼ 0.01 with respect to wild-type B-MYB, n ¼ 4).
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R Schwab et al in a different susceptibility to trypsin digestion (KimchiSarfaty et al., 2007) . Indeed, the digestion profile of the wild-type protein is markedly different from that of the polymorphic variants, demonstrating that a single amino-acid change is sufficient to alter B-MYB structure (Figure 1a) . B-MYB, like other members of the MYB family, is a transcriptional activator that recognizes the MYB-binding sequence C/TAACNG in target promoters. Transactivation of the classical MYB-responsive promoter MIM-1 is more easily detected in the human neuroblastoma cell line SHSY5Y than in 293 cells; thus, the former were used in transient transfection assays to compare the transactivating activity of the different B-MYB isoforms. Interestingly, the transactivating activity of the I624M isoform (indicated by the codon ATG in the figures) was markedly reduced compared to that of the wild-type protein, whereas the S427G polymorphism (indicated by the codon GGC) caused a less pronounced decrease of B-MYB transactivating activity ( Figure 1b ). Both B-MYB variants were able to partially suppress wild-type B-MYB transactivation demonstrating that, at least potentially, they could behave as mild dominantnegative alleles in carrier individuals ( Supplementary  Figure 1) . B-MYB has been shown to promote cell survival (Grassilli et al., 1999; Ahlbory et al., 2005) and we wanted to assess whether the polymorphisms modified its antiapoptotic activity. We transfected 293 cells with the wild-type or polymorphic B-MYB variants and exposed transfected cells to H 2 O 2 . The different B-MYB isoforms were equally expressed in 293 cells (Figure 2a ). To monitor cell death, we counted the number of cells containing sub-G 1 DNA. As expected, we observed that cells expressing ectopic B-MYB were protected from death caused by H 2 O 2 . The polymorphic B-MYB isoforms also protected 293 cells from cell death; however, we noticed a small but reproducible increase of DNA fragmentation in their presence (Figure 2b ). To further validate this finding, we assessed whether ectopic expression of B-MYB antagonized the activation of caspase 3, a classical marker of apoptosis. Once again, B-MYB strongly suppressed caspase-3 activation following exposure to H 2 O 2 , while the polymorphic variants were slightly, but significantly, less efficient (Figure 2c ). The activity of B-MYB and its variants was not noticeable in unstressed cells since apoptosis and cell cycle profiles were similar in naive 293 cells transfected with the different plasmids (Supplementary Figure 2 and Table 1 ). If the B-MYB variants have reduced transcriptional and antiapoptotic activities, downstream target genes should be differentially regulated. This hypothesis was investigated by assessing gene expression patterns after transient overexpression of the B-MYB variants in 293 cells exposed to H 2 O 2 . Affymetrix gene chip analysis shows that there are several genes differentially regulated by the different B-MYB isoforms. In particular, the expression of a number of regulators of cell proliferation and/or survival was downregulated in cells transfected with the polymorphic variants compared to cells transfected with wild-type B-MYB (the complete list of differentially regulated genes is shown in Supplementary  Table 2 ). The Affymetrix assay was validated by quantitative PCR (Q-PCR) analysis of two of the genes whose expression appeared to be downregulated in cells transfected with the B-MYB variants. Overexpression of wild-type B-MYB did not significantly increase transcription of NFAT4 or cdc25a. However, the polymorphic variants, in agreement with the microarray experiment, repressed basal NFTAT4 and cdc25a transcription, lending further support to the hypothesis that the polymorphisms might transform B-MYB in a mild dominant-negative molecule (Figure 3 ). NFAT4 is a transcription factor that promotes cell survival and cdc25a is a component of the cell cycle machinery often overexpressed in human cancer (Oukka et al., 1998; Eckstein et al., 2005; Boutros et al., 2006) . Together, these results suggest that the polymorphisms induce a change of protein conformation that partially inactivates B-MYB function. After 18 h cells were harvested and cDNA prepared for Q-PCR analysis. Total cellular RNA was extracted with the Trizol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). RNAs were reverse transcribed using a kit (Invitrogen). The PCR reaction was composed as follows: 1 ml cDNA, 1 ml 20Â primer/probe mix (CDC25A, NFAT4 and GAPDH; primers were purchased from Applied Biosystems, Foster City, CA, USA) and 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems) in a final volume of 20 ml. Values in the y axis represent NFAT4 and cdc25a mRNA expression levels relative to the values obtained with empty vectortransfected cells (indicated by control). Each column is the mean of triplicate assays and standard deviations are indicated by the error bars.
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Low penetrance genetic variations form the most essential component of heritability of cancer risk. SNPs, like certain rare alleles of the H-ras oncogene, appear to modulate the risk of human cancer (Sugimura et al., 1990; Imyanitov et al., 2004) , but common variant alleles would be more important since they may account for higher population-attributable risk. In the light of the findings described above, one could speculate that subjects carrying B-MYB polymorphisms might have a reduced risk of developing cancer because overexpression of the less functional minor alleles would not be as detrimental as that of the more efficient major allele. To test this hypothesis, we assessed the frequency of the different B-MYB alleles in normal individuals and cancer patients. Case and control samples were all gathered in Italy from individuals born in different geographical locations. We firstly noticed that the polymorphism rs2070235 (that is, G427I or GGC in the figures) is common in the Italian population with about 27% of heterozygote carriers. The other polymorphism rs11556379 (that is, I624M or ATG in the figures) is less common, with about 14% of heterozygote carriers. Correct genotyping was confirmed by sequencing about 25% of the samples and, as a further control, we verified that the observed allele frequencies were in agreement with the Hardy-Weinberg equilibrium (P ¼ 0.14 for rs2070235; P ¼ 0.52 for rs11556379). A search in the Human Genome Database confirmed that rs2070235 is frequent in other ethnical groups, being found in 10% of American Caucasians and almost 50% of subjects with African descent. The frequency of rs11556379 in other populations is unknown. We observed that the B-MYB polymorphisms are significantly less frequent in cancer patients than normal individuals. Compared to noncarriers, individuals bearing either polymorphism have a risk of developing cancer reduced to approximately half (Table 1) .
In summary, we found that about 40% of Italians carry B-MYB polymorphisms that confer a significant (Iacoviello et al., 1998) . The remaining 130 control DNAs were gathered in different Italian hospitals from over 65 years noncancer patients. Using as controls individuals who have already passed most of the period of cancer likelihood-that is elderly tumor-free individuals-has been suggested to be more appropriate than using age-adjusted controls (Imyanitov et al., 2004) . The subjects were all Italians and were distributed throughout the main Italian geographic areas. Control recruitment was carried out according to the Declaration of Helsinki of 1975. DNA samples were made anonymous before genetic testing. DNA samples from cancer patients (130 neuroblastomas, 126 chronic myelogenous leukaemias, 163 colon carcinomas) were extracted from peripheral blood, with the exception that neuroblastoma patients' DNA were extracted from tumor biopsies. To confirm that the polymorphisms in neuroblastoma samples were genuine, available matched blood samples were sequenced with 100% concordance. Patients are representative of Italian individuals born in different geographical areas. Written informed consent was obtained to perform genetic studies, which were approved by the local ethical committee. DNA samples were made anonymous before genetic testing. DNA samples from primary tumors or peripheral blood were genotyped by multiplex capillary heteroduplex analysis or DHPLC. Correct genotyping was confirmed by sequencing approximately 25% of the samples. The statistical significance of the differences was assessed using the w 2 -test. Where indicated by an asterisk (*), the Fisher's exact test was applied.
Functional characterization of B-MYB polymorphisms R Schwab et al reduction of cancer risk. It will be important to independently validate this finding using a larger number of cases and studying other ethnical backgrounds. If our observations will be confirmed, screening populations for these alleles may be useful to identify large segments of the public that are at more or less risk of developing neoplastic disease.
